SLC16A1 and type 2 diabetes mellitus: More recently, Liang et al. (2015) showed that miR-495 targets Slc16a1 in human embryonic stem cell (hESC) derived pancreatic endoderm that improved T2D symptoms upon transplantation in a murine model for T2D.